Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) Target Price at $11.50

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been assigned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $11.50.

Several brokerages have recently weighed in on HCAT. Wells Fargo & Company lowered their price objective on shares of Health Catalyst from $14.00 to $13.00 and set an “overweight” rating on the stock in a research note on Friday, May 10th. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 price target on shares of Health Catalyst in a research report on Tuesday, May 21st. Stephens cut their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research note on Friday, August 9th. Finally, Evercore ISI lowered their target price on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 9th.

Insider Transactions at Health Catalyst

In related news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $6.19, for a total transaction of $32,243.71. Following the sale, the chief operating officer now owns 150,006 shares of the company’s stock, valued at approximately $928,537.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 13,035 shares of company stock valued at $81,396 over the last 90 days. Company insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently modified their holdings of HCAT. Valmark Advisers Inc. purchased a new position in Health Catalyst during the 4th quarter valued at approximately $1,204,000. Primecap Management Co. CA grew its holdings in shares of Health Catalyst by 26.7% in the fourth quarter. Primecap Management Co. CA now owns 1,419,577 shares of the company’s stock valued at $13,145,000 after purchasing an additional 299,139 shares in the last quarter. Kennedy Capital Management LLC bought a new stake in Health Catalyst in the first quarter worth $8,780,000. ClariVest Asset Management LLC raised its stake in Health Catalyst by 303.9% during the first quarter. ClariVest Asset Management LLC now owns 282,325 shares of the company’s stock valued at $2,126,000 after purchasing an additional 212,425 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in Health Catalyst by 38.3% during the first quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock valued at $5,453,000 after purchasing an additional 200,494 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Up 1.3 %

Shares of HCAT stock opened at $6.84 on Friday. The company has a 50 day moving average price of $6.62 and a 200-day moving average price of $7.15. Health Catalyst has a 52 week low of $5.42 and a 52 week high of $12.05. The firm has a market capitalization of $403.80 million, a PE ratio of -3.70 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative net margin of 35.56% and a negative return on equity of 11.86%. The business had revenue of $75.90 million during the quarter, compared to analyst estimates of $74.96 million. During the same period in the previous year, the business earned ($0.21) EPS. The company’s quarterly revenue was up 3.7% compared to the same quarter last year. Analysts anticipate that Health Catalyst will post -0.4 earnings per share for the current year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.